A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia
Latest Information Update: 16 May 2025
At a glance
- Drugs VERVE 201 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
Most Recent Events
- 11 Nov 2024 Status changed from not yet recruiting to recruiting.
- 08 Dec 2023 New trial record
- 07 Nov 2023 According to a Verve Therapeutics media release, following regulatory clearance, the company expect to initiate this trial in the second half of 2024.